Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 235

1.

Sexual risk behavior among HIV-uninfected men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United States.

Liu AY, Vittinghoff E, Chillag K, Mayer K, Thompson M, Grohskopf L, Colfax G, Pathak S, Gvetadze R, Oʼhara B, Collins B, Ackers M, Paxton L, Buchbinder SP.

J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):87-94. doi: 10.1097/QAI.0b013e31828f097a.

2.

Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States.

Grohskopf LA, Chillag KL, Gvetadze R, Liu AY, Thompson M, Mayer KH, Collins BM, Pathak SR, Oʼhara B, Ackers ML, Rose CE, Grant RM, Paxton LA, Buchbinder SP.

J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):79-86. doi: 10.1097/QAI.0b013e31828ece33.

PMID:
23466649
3.

Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services.

Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, Chege W, Postle BS, Matheson T, Amico KR, Liegler T, Rawlings MK, Trainor N, Blue RW, Estrada Y, Coleman ME, Cardenas G, Feaster DJ, Grant R, Philip SS, Elion R, Buchbinder S, Kolber MA.

JAMA Intern Med. 2016 Jan;176(1):75-84. doi: 10.1001/jamainternmed.2015.4683.

4.

Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco.

Liu AY, Vittinghoff E, Sellmeyer DE, Irvin R, Mulligan K, Mayer K, Thompson M, Grant R, Pathak S, O'Hara B, Gvetadze R, Chillag K, Grohskopf L, Buchbinder SP.

PLoS One. 2011;6(8):e23688. doi: 10.1371/journal.pone.0023688. Epub 2011 Aug 29.

5.

Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial.

Sagaon-Teyssier L, Suzan-Monti M, Demoulin B, Capitant C, Lorente N, Préau M, Mora M, Rojas Castro D, Chidiac C, Chas J, Meyer L, Molina JM, Spire B; ANRS IPERGAY Study Group.

AIDS Care. 2016;28 Suppl 1:48-55. doi: 10.1080/09540121.2016.1146653. Epub 2016 Feb 17.

6.

No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis.

Marcus JL, Glidden DV, Mayer KH, Liu AY, Buchbinder SP, Amico KR, McMahan V, Kallas EG, Montoya-Herrera O, Pilotto J, Grant RM.

PLoS One. 2013 Dec 18;8(12):e81997. doi: 10.1371/journal.pone.0081997. eCollection 2013.

7.

Risk behaviors and risk factors for HIV infection among participants in the Bangkok tenofovir study, an HIV pre-exposure prophylaxis trial among people who inject drugs.

Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Gvetadze RJ, Kittimunkong S, Curlin ME, Worrajittanon D, McNicholl JM, Paxton LA, Choopanya K; Bangkok Tenofovir Study Group.

PLoS One. 2014 Mar 25;9(3):e92809. doi: 10.1371/journal.pone.0092809. eCollection 2014.

8.

Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco.

Gilmore HJ, Liu A, Koester KA, Amico KR, McMahan V, Goicochea P, Vargas L, Lubensky D, Buchbinder S, Grant R.

AIDS Patient Care STDS. 2013 Oct;27(10):560-6. doi: 10.1089/apc.2013.0116.

9.

Acceptability of an "on-demand" pre-exposure HIV prophylaxis trial among men who have sex with men living in France.

Lorente N, Fugon L, Carrieri MP, Andreo C, Le Gall JM, Cook E, Aboulker JP, Capitant C, Molina JM, Spire B.

AIDS Care. 2012;24(4):468-77. doi: 10.1080/09540121.2011.626394. Epub 2011 Nov 15.

PMID:
22085083
10.

HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial.

Buchbinder SP, Glidden DV, Liu AY, McMahan V, Guanira JV, Mayer KH, Goicochea P, Grant RM.

Lancet Infect Dis. 2014 Jun;14(6):468-75. doi: 10.1016/S1473-3099(14)70025-8. Epub 2014 Mar 7.

11.

A randomized control trial of personalized cognitive counseling to reduce sexual risk among HIV-infected men who have sex with men.

Schwarcz SK, Chen YH, Murphy JL, Paul JP, Skinta MD, Scheer S, Vittinghoff E, Dilley JW.

AIDS Care. 2013;25(1):1-10. doi: 10.1080/09540121.2012.674095. Epub 2012 May 9.

PMID:
22568569
12.

Acceptability of pre-exposure prophylaxis among men who have sex with men and transgender women in Northern Thailand.

Yang D, Chariyalertsak C, Wongthanee A, Kawichai S, Yotruean K, Saokhieo P, Guadamuz T, Suwanvanichkij V, Beyrer C, Chariyalertsak S.

PLoS One. 2013 Oct 8;8(10):e76650. doi: 10.1371/journal.pone.0076650. eCollection 2013.

13.

High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project.

Cohen SE, Vittinghoff E, Bacon O, Doblecki-Lewis S, Postle BS, Feaster DJ, Matheson T, Trainor N, Blue RW, Estrada Y, Coleman ME, Elion R, Castro JG, Chege W, Philip SS, Buchbinder S, Kolber MA, Liu AY.

J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):439-48. doi: 10.1097/QAI.0000000000000479.

14.

Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men.

Johnson WD, Diaz RM, Flanders WD, Goodman M, Hill AN, Holtgrave D, Malow R, McClellan WM.

Cochrane Database Syst Rev. 2008 Jul 16;(3):CD001230. doi: 10.1002/14651858.CD001230.pub2. Review.

PMID:
18646068
15.

Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.

Hosek SG, Landovitz RJ, Kapogiannis B, Siberry GK, Rudy B, Rutledge B, Liu N, Harris DR, Mulligan K, Zimet G, Mayer KH, Anderson P, Kiser JJ, Lally M, Brothers J, Bojan K, Rooney J, Wilson CM.

JAMA Pediatr. 2017 Nov 1;171(11):1063-1071. doi: 10.1001/jamapediatrics.2017.2007.

PMID:
28873128
16.

Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study).

King HL, Keller SB, Giancola MA, Rodriguez DA, Chau JJ, Young JA, Little SJ, Smith DM.

AIDS Behav. 2014 Sep;18(9):1722-5. doi: 10.1007/s10461-014-0845-5.

17.

Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.

Okwundu CI, Uthman OA, Okoromah CA.

Cochrane Database Syst Rev. 2012 Jul 11;(7):CD007189. doi: 10.1002/14651858.CD007189.pub3. Review.

PMID:
22786505
18.

High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis.

Matthews LT, Heffron R, Mugo NR, Cohen CR, Hendrix CW, Celum C, Bangsberg DR, Baeten JM; Partners PrEP Study Team.

J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):91-7. doi: 10.1097/QAI.0000000000000246.

19.

An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis.

Dolling DI, Desai M, McOwan A, Gilson R, Clarke A, Fisher M, Schembri G, Sullivan AK, Mackie N, Reeves I, Portman M, Saunders J, Fox J, Bayley J, Brady M, Bowman C, Lacey CJ, Taylor S, White D, Antonucci S, Gafos M, McCormack S, Gill ON, Dunn DT, Nardone A; PROUD Study Group.

Trials. 2016 Mar 24;17:163. doi: 10.1186/s13063-016-1286-4.

20.

An intervention to reduce HIV risk behavior of substance-using men who have sex with men: a two-group randomized trial with a nonrandomized third group.

Mansergh G, Koblin BA, McKirnan DJ, Hudson SM, Flores SA, Wiegand RE, Purcell DW, Colfax GN; Project MIX Study Team.

PLoS Med. 2010 Aug 24;7(8):e1000329. doi: 10.1371/journal.pmed.1000329.

Supplemental Content

Support Center